All Stories

  1. Recent Advances in Vaccine Development for Flaviviruses and Alphaviruses
  2. Chikungunya Virus: Priority Pathogen or Passing Trend?
  3. Recent Developments in Vaccines against Flaviviruses and Alphaviruses
  4. Parameters to Predict the Outcome of Severe and Critical COVID-19 Patients when Admitted to the Hospital
  5. Vaccines Against SARS-CoV-2. Eradicating COVID-19
  6. Development of Viral-Vectored Vaccines and Virus Replicon Particle-Based Neutralisation Assay against Mayaro Virus
  7. Cutting Edge: Subunit Booster Vaccination Confers Sterilizing Immunity against Liver-Stage Malaria in Mice Initially Primed with a Weight-Normalized Dose of Radiation-Attenuated Sporozoites
  8. Dengue Virus Induces the Expression and Release of Endocan from Endothelial Cells by an NS1–TLR4-Dependent Mechanism
  9. A VLP for validation of the Plasmodium falciparum circumsporozoite protein junctional epitope for vaccine development
  10. Low immunogenicity of malaria pre‐erythrocytic stages can be overcome by vaccination
  11. Discovery of four new B-cell protective epitopes for malaria using Q beta virus-like particle as platform
  12. Importance of the Immunodominant CD8+T Cell Epitope of Plasmodium berghei Circumsporozoite Protein in Parasite- and Vaccine-Induced Protection
  13. Low immunogenicity of malaria pre-erythrocytic stages can be overcome by vaccination
  14. Chikungunya E2 Protein Produced in E. coli and HEK293-T Cells—Comparison of Their Performances in ELISA
  15. Evaluation of Chimpanzee Adenovirus and MVA Expressing TRAP and CSP from Plasmodium cynomolgi to Prevent Malaria Relapse in Nonhuman Primates
  16. Immunogenicity and Efficacy of Zika Virus Envelope Domain III in DNA, Protein, and ChAdOx1 Adenoviral-Vectored Vaccines
  17. Protective efficacy of peptides from Plasmodium vivax circumsporozoite protein
  18. Drug-cured experimental Trypanosoma cruzi infections confer long-lasting and cross-strain protection
  19. Considering Genomic and Immunological Correlates of Protection for a Dengue Intervention
  20. A Single and Un-Adjuvanted Dose of a Chimpanzee Adenovirus-Vectored Vaccine against Chikungunya Virus Fully Protects Mice from Lethal Disease
  21. Assessment of Immunogenicity and Efficacy of a Zika Vaccine Using Modified Vaccinia Ankara Virus as Carriers
  22. A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection
  23. Immunity conferred by drug-cured experimental Trypanosoma cruzi infections is long-lasting and cross-strain protective
  24. Publisher Correction: Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria
  25. 51 years in of Chikungunya clinical vaccine development: A historical perspective
  26. A Zika vaccine based on chimpanzee adenovirus ChAdOx1 elicits lineage-transcending sterile immunity and prevents colonisation of brain and ovaries
  27. A probabilistic model of pre-erythrocytic malaria vaccine combination in mice
  28. Rapid travel to a Zika vaccine: are we heading towards success or more questions?
  29. Tailoring aPlasmodium vivaxVaccine To Enhance Efficacy through a Combination of a CSP Virus-Like Particle and TRAP Viral Vectors
  30. Adjuvanting a viral vectored vaccine against pre-erythrocytic malaria
  31. Detecting circulating antibodies by controlled surface modification with specific target proteins: Application to malaria
  32. A highly protective P. vivax CSP vaccine
  33. Evaluation of Plasmodium vivax Cell-Traversal Protein for Ookinetes and Sporozoites as a Preerythrocytic P. vivax Vaccine
  34. Influence of adenovirus and MVA vaccines on the breadth and hierarchy of T cell responses
  35. Impact of Reducing Complement Inhibitor Binding on the Immunogenicity of Native Neisseria meningitidis Outer Membrane Vesicles
  36. Tailoring a Combination Preerythrocytic Malaria Vaccine
  37. Acquisition and Longevity of Antibodies to Plasmodium vivax Preerythrocytic Antigens in Western Thailand
  38. Transient IL-10 receptor blockade can enhance CD8+T cell responses to a simian adenovirus-vectored HIV-1 conserved region immunogen
  39. Efficacy of a Plasmodium vivax Malaria Vaccine Using ChAd63 and Modified Vaccinia Ankara Expressing Thrombospondin-Related Anonymous Protein as Assessed with Transgenic Plasmodium berghei Parasites
  40. Plasmodium vivax malaria vaccines: Why are we where we are?
  41. Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation
  42. Evaluation of the Safety and Immunogenicity of a Candidate Tuberculosis Vaccine, MVA85A, Delivered by Aerosol to the Lungs of Macaques
  43. Immunogenicity and efficacy of a chimpanzee adenovirus-vectored Rift Valley Fever vaccine in mice
  44. Optimising Immunogenicity with Viral Vectors: Mixing MVA and HAdV-5 Expressing the Mycobacterial Antigen Ag85A in a Single Injection
  45. A novel Plasmodium vivax vaccine based on recombinant chimpanzee adenovirus ChAd63 and MVA expressing TRAP
  46. Mixed Vector Immunization With Recombinant Adenovirus and MVA Can Improve Vaccine Efficacy While Decreasing Antivector Immunity
  47. Small Cationic DDA:TDB Liposomes as Protein Vaccine Adjuvants Obviate the Need for TLR Agonists in Inducing Cellular and Humoral Responses
  48. Superior Induction of T Cell Responses to Conserved HIV-1 Regions by Electroporated Alphavirus Replicon DNA Compared to That with Conventional Plasmid DNA Vaccine
  49. Clinical Assessment of a Recombinant Simian Adenovirus ChAd63: A Potent New Vaccine Vector
  50. CD8+ T Effector Memory Cells Protect against Liver-Stage Malaria
  51. Viral vectors as vaccine platforms: deployment in sight
  52. Correction: Single-dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei
  53. Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8+T-Cell Responses
  54. Immune responses against a liver-stage malaria antigen induced by simian adenoviral vector AdCh63 and MVA prime–boost immunisation in non-human primates
  55. Prime-boost vectored malaria vaccines: Progress and prospects
  56. Prime-Boost Immunization with Adenoviral and Modified Vaccinia Virus Ankara Vectors Enhances the Durability and Polyfunctionality of Protective Malaria CD8+ T-Cell Responses
  57. Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria
  58. Single‐dose immunogenicity and protective efficacy of simian adenoviral vectors against Plasmodium berghei
  59. Single-Dose Protection against Plasmodium berghei by a Simian Adenovirus Vector Using a Human Cytomegalovirus Promoter Containing Intron A
  60. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines
  61. Viral vector vaccines make memory T cells against malaria
  62. Anti-tumor DNA vaccines based on the expression of human papillomavirus-16 E6/E7 oncoproteins genetically fused with the glycoprotein D from herpes simplex virus-1
  63. Oral Vaccination of Mice with Adenoviral Vectors Is Not Impaired by Preexisting Immunity to the Vaccine Carrier
  64. Human Immunodeficiency Virus Type 1-Specific Immune Responses in Primates upon Sequential Immunization with Adenoviral Vaccine Carriers of Human and Simian Serotypes
  65. CpG Methylation of a Plasmid Vector Results in Extended Transgene Product Expression by Circumventing Induction of Immune Responses
  66. Oral Vaccination of Mice with Adenoviral Vectors Is Not Impaired by Preexisting Immunity to the Vaccine Carrier
  67. Chemokines and TRANCE as genetic adjuvants for a DNA vaccine to rabies virus
  68. Novel, Chimpanzee Serotype 68-Based Adenoviral Vaccine Carrier for Induction of Antibodies to a Transgene Product
  69. DNA Vaccines.